Li­nus­Bio se­cures Se­ries A for di­ag­nos­tic plat­form that us­es a sin­gle strand of hair

Li­nus­Bio, a Mount Sinai spin­off start­ing out fo­cused on neu­ro­log­i­cal dis­or­ders like autism, an­nounced Thurs­day it raised $16 mil­lion in Se­ries A fund­ing.

Pro­ceeds will go to­ward build­ing its plat­form that us­es ex­po­some bio­mark­ers with the aim of im­prov­ing and quick­en­ing the di­ag­no­sis of health con­di­tions as well as mea­sure re­spons­es to en­vi­ron­men­tal ex­po­sure.

Ac­cord­ing to the New York-based com­pa­ny, the plat­form ex­am­ines pa­tients at the mol­e­c­u­lar lev­el and can pro­vide da­ta from a sin­gle strand of hair equal to over 500 liq­uid biop­sies or blood sam­ples to catch health con­di­tions that ge­nom­ic bio­mark­ers can’t and “maps the mol­e­c­u­lar dy­nam­ics of hu­man phys­i­ol­o­gy in a time-de­pen­dent man­ner.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER